Skip to Main Content
Skip Nav Destination

Glioma Approval Sets New Course in Pediatric Drug Development

May 14, 2024

The repositioning of shelved assets for pediatric applications presents a promising avenue for advancing therapies for childhood tumors. Tovorafenib, originally intended for adult melanoma, received approval in April as a treatment for pediatric low-grade glioma. This success has spurred hopes within the industry of replicating this achievement with other previously discontinued drug candidates.

You do not currently have access to this content.
Don't already have an account? Register
Close Modal

or Create an Account

Close Modal
Close Modal